TGR5 ligands as potential therapeutics in inflammatory diseases

International Journal of Interferon, Cytokine and Mediator Research

Volumn 6, Issue 1, 2014, Pages 27-38

  Eggink, Hannah M ^a   Soeters, Maarten R ^a   Pols, Thijs W H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Bile acids; G protein coupled receptor; Inflammation; Macrophages; Metabolism; Takeda G protein coupled receptor 5

Indexed keywords

1 [6 FLUORO 2 METHYL 3,4 DIHYDROQUINOLIN (2H) YL] 2 (ISOQUINOLIN 5 YLOXY)ETHANONE; 1,4 BIS[(3,4 BIS(METHYLOXY)PHENYL) SULFONYL]HEXAHYDRO 1H 1,4 DIAZEPINE; 3 ARYL 4 ISOXAZOLECARBOXAMIDE DERIVATIVE; 5 PHENOXY 1,3 DIMETHYL 1H PYRAZOLE 4 CARBOXAMIDE DERIVATIVE; 6 METHYL 2 OXO 4 THIOPHEN 2 YL 1,2,3,4 TETRAHYDROPYRIMIDINE 5 CARBOXYLIC ACID BENZYL ESTER; 6ALPHA ETHYL 23 METHYLCHOLIC ACID; ANTIINFLAMMATORY AGENT; BETULIC ACID; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INT 767; INT 777; N [4 CHLOROPHENYL] 2 [4 FLUOROPHENOXY] N METHYLIMIDAZO[1,2 A] PYRIMIDINE 3 CARBOXAMIDE; OBETICHOLIC ACID; SB 756050; TAKEDA G PROTEIN COUPLED RECEPTOR 5; TAKEDA G PROTEIN COUPLED RECEPTOR 5 AGONIST; TRC 210258; UNCLASSIFIED DRUG; URSOLIC ACID; XL 475;

ATHEROSCLEROSIS; BILE ACID SYNTHESIS; CARCINOGENESIS; CHOLESTASIS; COLITIS; DENDRITIC CELL; DRUG ACTIVATION; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; ENERGY EXPENDITURE; ENZYME ACTIVATION; GALLSTONE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATORY DISEASE; MACROPHAGE; MONOCYTE; NERVOUS SYSTEM; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PRURITUS; REVIEW; SIGNAL TRANSDUCTION;

EID: 84940300893     PISSN: None     EISSN: 1179139X     Source Type: Journal    
DOI: 10.2147/IJICMR.S40102     Document Type: Review

References (92)

1. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008; 7(8): 678-693.
2. Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 2013; 53: 531-556.
3. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11): 9435-9440.
4. Maruyama T, Miyamoto Y, Nakamura T, et al. Identif ication of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002; 298(5): 714-719.
5. Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011; 14(6): 747-757.
6. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagonlike peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005; 329(1): 386-390.
7. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009; 10(3): 167-177.
8. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006; 439(7075): 484-489.
9. Pols TW. TGR5 in inflammation and cardiovascular disease. Biochem Soc Trans. 2014; 42(2): 244-249.
10. Sato H, Macchiarulo A, Thomas C, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008; 51(6): 1831-1841.
11. Iguchi Y, Yamaguchi M, Sato H, Kihira K, Nishimaki-Mogami T, Une M. Bile alcohols function as the ligands of membrane-type bile acid-activated G protein-coupled receptor. J Lipid Res. 2010; 51(6): 1432-1441.
12. Keitel V, Görg B, Bidmon HJ, et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia. 2010; 58(15): 1794-1805.
13. Ono E, Inoue J, Hashidume T, Shimizu M, Sato R. Anti-obesity and anti-hyperglycemic effects of the dietary citrus limonoid nomilin in mice fed a high-fat diet. Biochem Biophys Res Commun. 2011; 410(3): 677-681.
14. Gioiello A, Rosatelli E, Nuti R, Macchiarulo A, Pellicciari R. Patented TGR5 modulators: a review (2006-present). Expert Opin Ther Pat. 2012; 22(12): 1399-1414.
15. Spomer L, Gertzen CG, Schmitz B, Häussinger D, Gohlke H, Keitel V. A membrane-proximal, C-terminal α-helix is required for plasma membrane localization and function of the G Protein-coupled receptor (GPCR) TGR5. J Biol Chem. 2014; 289(6): 3689-3702.
16. Jensen DD, Godfrey CB, Niklas C, et al. The bile acid receptor TGR5 does not interact with β-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. J Biol Chem. 2013; 288(32): 22942-22960.
17. Hong J, Behar J, Wands J, et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut. 2010; 59(2): 170-180.
18. Cao W, Tian W, Hong J, et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol. 2013; 304(4): G322-G327.
19. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. NatRev Mol Cell Biol. 2002; 3: 639-650.
20. Masyuk AI, Huang BQ, Radtke BN, et al. Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol. 2013; 304(11): G1013-G1024.
21. Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiba M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun. 2007; 354(1): 154-159.
22. Yang JI, Yoon JH, Myung SJ, et al. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase8activation in hepatocytes. Biochem Biophys Res Commun. 2007; 361(1): 156-161.
23. Hov JR, Keitel V, Laerdahl JK, et al; IBSEN Study Group. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One. 2010; 5(8): e12403.
24. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Häussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology. 2009; 50(3): 861-870.
25. Vassileva G, Golovko A, Markowitz L, et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J. 2006; 398(3): 423-430.
26. Lavoie B, Balemba OB, Godfrey C, et al. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J Physiol. 2010; 588(Pt17): 3295-3305.
27. Li T, Holmstrom SR, Kir S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol. 2011; 25(6): 1066-1071.
28. Maruyama T, Tanaka K, Suzuki J, et al. Targeted disruption of G protein-coupled bile acid receptor1 (Gpbar1/M-Bar) in mice. J Endocrinol. 2006; 191(1): 197-205.
29. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol. 2011; 54(6): 1263-1272.
30. Harach T, Pols TW, Nomura M, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep. 2012; 2: 430.
31. Potthoff MJ, Potts A, He T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol. 2013; 304(4): G371-G380.
32. Ockenga J, Valentini L, Schuetz T, et al. Plasma bile acids are associated with energy expenditure and thyroid function in humans. J Clin Endocrinol Metab. 2012; 97(2): 535-542.
33. Poole DP, Godfrey C, Cattaruzza F, et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil. 2010; 22(7): 814-825, e227.
34. Camilleri M, Vazquez-Roque MI, Carlson P, Burton D, Wong BS, Zinsmeister AR. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol Motil. 2011; 23(11): 995-999, e458.
35. Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest. 2013; 123(4): 1513-1530.
36. Ogundare M, Theofilopoulos S, Lockhart A, et al. Cerebrospinal fluid steroidomics: are bioactive bile acids present in brain? J Biol Chem. 2010; 285(7): 4666-4679.
37. Mano N, Goto T, Uchida M, et al. Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain. J Lipid Res. 2004; 45(2): 295-300.
38. Kitazawa T, Terasaki T, Suzuki H, Kakee A, Sugiyama Y. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. J Pharmacol Exp Ther. 1998; 286(2): 890-895.
39. Parry GJ, Rodrigues CM, Aranha MM, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. 2010; 33(1): 17-21.
40. Sato H, Genet C, Strehle A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun. 2007; 362(4): 793-798.
41. Macchiarulo A, Gioiello A, Thomas C, et al. Molecular field analysis and 3D-quantitative structure-activity relationship study (MFA3D-QSAR) unveil novel features of bile acid recognition at TGR5. J Chem Inf Model. 2008; 48(9): 1792-1801.
42. Macchiarulo A, Gioiello A, Thomas C, et al. Probing the binding site of bile acids in TGR5. ACS Med Chem Lett. 2013; 4(12): 1158-1162.
43. Rizzo G, Passeri D, De Franco F, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol. 2010; 78(4): 617-630.
44. Pellicciari R, Gioiello A, Macchiarulo A, et al. Discovery of6alphaethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem. 2009; 52(24): 7958-7961.
45. Rizzo G, Disante M, Mencarelli A, et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol. 2006; 70(4): 1164-1173.
46. Pellicciari R, Gioiello A, Sabbatini P, et al. Avicholic acid: a lead compound from birds on the route to potent TGR5 modulators. ACS Med Chem Lett. 2012; 3(4): 273-277.
47. Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic βcells. Biochem Biophys Res Commun. 2012; 427(3): 600-605.
48. Ward JB, Mroz MS, Keely SJ. The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon. Neurogastroenterol Motil. 2013; 25(8): 708-711.
49. Iguchi Y, Nishimaki-Mogami T, Yamaguchi M, Teraoka F, Kaneko T, Une M. Effects of chemical modification of ursodeoxycholic acid on TGR5 activation. Biol Pharm Bull. 2011; 34(1): 1-7.
50. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer. 2007; 7(5): 357-369.
51. Genet C, Strehle A, Schmidt C, et al. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem. 2010; 53(1): 178-190.
52. Inoue T, Wang JH, Higashiyama M, et al. Dipeptidyl peptidase IV inhibition potentiates amino acid-and bile acid-induced bicarbonate secretion in rat duodenum. Am J Physiol Gastrointest Liver Physiol. 2012; 303(7): G810-G816.
53. Yoon JJ, Lee YJ, Kim JS, Kang DG, Lee HS. Betulinic acid inhibits high glucose-induced vascular smooth muscle cells proliferation and migration. J Cell Biochem. 2010; 111(6): 1501-1511.
54. de Melo CL, Queiroz MG, Arruda Filho AC, et al. Betulinic acid, a natural pentacyclic triterpenoid, prevents abdominal fat accumulation in mice fed a high-fat diet. J Agric Food Chem. 2009; 57(19): 8776-8781.
55. Jayaprakasam B, Olson LK, Schutzki RE, Tai MH, Nair MG. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). Journal of agricultural and food chemistry. 2006; 54(1): 243-248.
56. Jang SM, Kim MJ, Choi MS, Kwon EY, Lee MK. Inhibitory effects of ursolic acid on hepatic polyol pathway and glucose production in streptozotocin-induced diabetic mice. Metabolism. 2010; 59(4): 512-519.
57. Kunkel SD, Elmore CJ, Bongers KS, et al. Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One. 2012; 7(6): e39332.
58. Rao VS, de Melo CL, Queiroz MG, et al. Ursolic acid, a pentacyclic triterpene from Sambucus australis, prevents abdominal adiposity in mice fed a high-fat diet. J Med Food. 2011; 14(11): 1375-1382.
59. Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ; SB-756050 Project Team. Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type2 diabetes. Clinical Pharmacology in Drug Development. 2013; 2(3): 213-222.
60. Zambad SP, Tuli D, Mathur A, et al. TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity. Diabetes Metab Syndr Obes. 2013; 7: 1-14.
61. Evans KA, Budzik BW, Ross SA, et al. Discovery of3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J Med Chem. 2009; 52(24): 7962-7965.
62. Herbert MR, Siegel DL, Staszewski L, et al. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett. 2010; 20(19): 5718-5721.
63. Eng H, Niosi M, McDonald TS, et al. Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstableamide derivative and agonist of the TGR5 receptor. Xenobiotica. 2010; 40(6): 369-380.
64. Londregan AT, Piotrowski DW, Futatsugi K, et al. Discovery of 5-phenoxy-1, 3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries. Bioorg Med Chem Lett. 2013; 23(5): 1407-1411.
65. Cipriani S, Mencarelli A, Chini MG, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 2011; 6(10): e25637.
66. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23(11): 549-555.
67. Keitel V, Donner M, Winandy S, Kubitz R, Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun. 2008; 372(1): 78-84.
68. Wang YD, Chen WD, Yu D, Forman BM, Huang W. The G-proteincoupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology. 2011; 54(4): 1421-1432.
69. Haselow K, Bode JG, Wammers M, et al. Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J Leukoc Biol. 2013; 94(6): 1253-1264.
70. Yoneno K, Hisamatsu T, Shimamura K, et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology. 2013; 139(1): 19-29.
71. Keitel V, Spomer L, Marin JJ, et al. Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta. 2013; 34(9): 810-816.
72. Ichikawa R, Takayama T, Yoneno K, et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology. 2012; 136(2): 153-162.
73. Keitel V, Reinehr R, Gatsios P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology. 2007; 45(3): 695-704.
74. Kida T, Tsubosaka Y, Hori M, Ozaki H, Murata T. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2013; 33(7): 1663-1669.
75. Cipriani S, Mencarelli A, Bruno A, et al. Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by nonsteroidal anti-inflammatory drugs and aspirin in mice. Br J Pharmacol. 2013; 168(1): 225-237.
76. Fryer RM, Ng KJ, Nodop Mazurek SG, et al. G protein-coupled bile acid receptor1 stimulation mediates arterial vasodilation through a K(Ca)1. 1 (BK(Ca)-dependent mechanism. J Pharmacol Exp Ther. 2014; 348(3): 421-431.
77. Kida T, Omori K, Hori M, Ozaki H, Murata T. Stimulation of G proteincoupled bile acid receptor enhances vascular endothelial barrier function via activation of protein kinase A and Rac1. J Pharmacol Exp Ther. 2014; 348(1): 125-130.
78. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. Epub 2014 Apr 13.
79. Steiner C, Othman A, Saely CH, et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One. 2011; 6(11): e25006.
80. Duboc H, Aelion H, Rainteau D, et al. Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor? Hepatology. 2012; 56(6): 2426.
81. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009; 51(1): 212-223.
82. Pellicciari R, Sato H, Gioiello A, et al. Nongenomic actions of bile acids. Synthesis and preliminary characterization of23-and6, 23-alkylsubstituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J Med Chem. 2007; 50(18): 4265-4268.
83. McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem. 2013; 288(17): 11761-11770.
84. Péan N, Doignon I, Garcin I, et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology. 2013; 58(4): 1451-1460.
85. Alemi F, Poole DP, Chiu J, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology. 2013; 144(1): 145-154.
86. Rajagopal S, Kumar DP, Mahavadi S, et al. Activation of G protein-coupled bile acid receptor, TGR5, induces smooth muscle relaxation via both Epac-and PKA-mediated inhibition of RhoA/Rho kinase pathway. Am J Physiol Gastrointest Liver Physiol. 2013; 304(5): G527-G535.
87. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Häussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology. 2009; 50(3): 861-870.
88. Casaburi I, Avena P, Lanzino M, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle. 2012; 11(14): 2699-2710.
89. Han LY, Fan YC, Mu NN, et al. Aberrant DNA methylation of G-proteincoupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B virus associated hepatocellular carcinoma. Int J Med Sci. 2014; 11(2): 164-171.
90. Gioiello A, Rosatelli E, Nuti R, Macchiarulo A, Pellicciari R. Patented TGR5 modulators: a review (2006-present). Expert Opin Ther Pat. 2012; 22(12): 1-16.
91. Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K. Biased signaling pathways in β2-adrenergic receptor characterized by19F-NMR. Science. 2012; 335(6072): 1106-1110.
92. Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: an updated review. Int J Pharm Investig. 2012; 2(1): 2-11.